Diamyd Medical Reports Results from Phase II Study in Cancer Pain

July 2012
Biomedical Market Newsletter;7/7/2012, Vol. 21, p1
The article informs that the drug NP2 Enkephalin developed by Diamyd Medical AB did not meet its primary objective of reducing pain in cancer patients. NP2 Enkephalin is based on the Medical's patented Nerve Targeting Drug Delivery System (NTDDS) platform and delivers the natural painkilling substance enkephalin directly to the nervous system for treating pain. The NTDDS technology provides a local effect in the body where the treatment is targeted without affecting the rest of the body.


Related Articles

  • Diamyd Completes Recruitment In Gene Therapy Pain Trial. Sheridan, Cormac // BioWorld International;5/23/2012, p2 

    The article reports on the six percent increase in the value of Diamyd Medical AB stocks after news that it completed recruitment in a Phase II trial of NP2 Enkephalin, its gene therapy treatment for chronic cancer pain. Study results are expected to have an impact on the company's future after...

  • Diamyd Medical: Qtrly Report III 11/12.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that Diamyd Medical AB has released its financial report for the fiscal year 2011 and 2012. The net sales amounted to MSEK 1.0 and loss before tax is said to be MSEK -23.2. According to chief executive officer (CEO) of the company, the Phase II study with the drug NP2...

  • Diamyd Medical's Phase II study in cancer pain fully recruited.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article presents information on the Diamyd Medical AB which has recruited the last patient for the treatment of cancer pain with the drug candidate NP2 Enkephalin. It informs that this clinical trial is the first placebo-controlled clinical trial of a drug candidate. As per Peter Zerhouni,...

  • Clinic Roundup.  // BioWorld Today;2/11/2011, Vol. 22 Issue 29, p2 

    This section offers news briefs on drug trials. A Phase II trial is being conducted by Diamyd Medical AB for its NP2 Enkephalin drug for the reduction of cancer pain. Enrollment in a Phase I trial of therapeutic caner vaccine DPX-0907 has been completed by Immunovaccine Inc. A Phase II trial of...

  • Clinic Roundup.  // BioWorld Today;5/23/2012, p5 

    This section offers news briefs on clinical trials. A Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron to treat peritumoral brain edema associated with cerebral tumors has been completed by Celtic Pharmaceutical Holdings LP....

  • Diamyd Medical: Diamyd Puts Focus on Pain Projects and Reduces Costs.  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p334 

    The article focuses on the shift in the primary development focus of Diamyd Medical AB from diabetes therapy to a portfolio of drug candidates for chronic pain and nervous diseases treatment. It states that the pain portfolio is based on the Nerve Targeting Drug Delivery System's (NTDDS)...

  • Diamyd Climbs on $625M Type I Diabetes Deal.  // Bioworld Week;6/28/2010, Vol. 18 Issue 26, p4 

    The article reports on the deal to develop the Type I diabetes, entered by Diamyd Medical AB in Sweden.

  • Information about Summons to the Annual General Meeting of Diamyd Medical AB.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p138 

    The article offers information on the Annual General Meeting of Diamyd Medical AB, to be held on December 7, 2011.

  • Prevention Study with Diamyd's Diabetes Vaccine Fully Recruited.  // Biomedical Market Newsletter;1/14/2012, Vol. 21, p1 

    The article offers information on a study conducted by a research group at the Lund University in Sweden. A total of 50 children aged four- years and older with a high risk of developing type 1 diabetes have been enrolled DiAPREV-IT, a researcher-initiated Phase II study with diabetes vaccine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics